Impact Factor
3.74
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.41
1,084 total citations
h5-index
28
h5 depth signal
Cited share
77.6%
198 of 255
Total citations
1,084
Citation footprint
Metric signal
4.09
External metric anchor
Self-citation
2.6%
28 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
997
United States
71
Italy
50
Japan
45
South Korea
29
Citing Fields of Research
Noncoding RNA
538
Cancer & Development
497
Oncology
376
Cancer, Autophagy & Apoptosis
246
Immunology
220
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,230
Articles tracked across the journal lifetime
Indexed publication set
255
198 cited publications
Last 12 months
387
387.0 publications/month
Open access share
92.2%
357 OA publications in the last year
Leading citing country
China
997 citing publications
Leading citing field
Noncoding RNA
538 citing publications
Latest tracked publication
1 January 2026
10 recent records available
Coverage & Indexing History
v4n1, 1992-
v4n1, 1992-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Cancer & Development
Immunology
Noncoding RNA
Cancer, Autophagy & Apoptosis
Lung Cancer
Broad Categories
Neoplasms
Noncoding RNA
Cancer, Autophagy & Apoptosis
Cancer & Development
Immunology
Cell Biology
Urology
MeSH Descriptors
Medical Oncology
Neoplasms
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.32604/or.2026.089696
Open DOI
Beyond a Molecular Link: Rethinking the Leptin–Leptin Receptor Axis in Thyroid Cancer
02
03
DOI 10.32604/or.2026.086330
Open DOI
Cyclin D1 Binds and Sequesters Overexpressed E2F1 in the Cytoplasm of Human Normal Fibroblasts
04
DOI 10.32604/or.2026.088024
Open DOI
Cancer-Associated Fibroblasts in Gastric Cancer Peritoneal Metastasis
Gastric cancer is a leading cause of cancer-related death worldwide; among its progression patterns, peritoneal metastasis (PM) has the poorest prognosis. PM lesions show strong resistance to immune checkpoint inhibitors (ICIs), and the ...
05
DOI 10.32604/or.2026.084842
Open DOI
CXCL9 Knockdown Inhibits Tumor Progression and Angiogenesis in Clear Cell Renal Cell Carcinoma via JAK-STAT3 Signaling Pathway
Background: Advanced clear cell renal cell carcinoma (ccRCC) has a poor prognosis and frequent targeted therapy resistance, which urgently requires novel prognostic biomarkers and therapeutic targets. This study aimed to screen hub genes...
06
DOI 10.32604/or.2026.087931
Open DOI
Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation
Objectives: Circular RNAs (circRNAs) can encode functional peptides to regulate tumor progression, yet the roles of circRNA-encoded peptides in epithelial ovarian cancer (EOC) remain poorly understood. This study aimed to investigate the...
07
DOI 10.32604/or.2026.086574
Open DOI
PRS-OPT–Guided Optimization Identifies a Metabolically Selective Combination of N-Acetylcysteine, Valproic Acid, and Indomethacin for Hepatocellular Carcinoma
Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma (HCC) is an increasingly prevalent HCC subtype characterized by metabolic reprogramming, inflammatory remodeling of the tumo...
08
DOI 10.32604/or.2026.089593
Open DOI
Epigenetic Dysregulation in Thyroid Cancer: From Molecular Mechanisms to Precision Oncology
Epigenetic dysregulation has emerged as a critical layer of molecular control in thyroid cancer (TC), complementing classical genetic alterations such as BRAF, RAS, and TERT promoter mutations. Aberrant DNA methylation, histone modificat...
09
DOI 10.32604/or.2026.084760
Open DOI
Biochanin A Induces Cuproptosis and Inhibits Lung Metastasis in triple-negative Breast Cancer
Background: Triple-negative breast cancer (TNBC) constitutes an invasive breast tumor subtype, marked by scarce available therapies and unfavorable patient prognosis. Natural products have attracted increasing attention as potential anti...
10
DOI 10.32604/or.2026.089550
Open DOI
Tumor Microenvironment-Mediated Resistance in HER2-Positive Breast Cancer: Recent Advances and Therapeutic Challenges
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with aggressive disease and poor prognosis. Despite advances in HER2-targeted therapies, resistance remains a major clinical challenge. This review focu...
Bibliographical & Catalog Notes
Also issued online.
Absorbed: Anti-cancer drug design.
Vol. 6, no. 12 (NONE 1994)19950516 Notice published Printed on acid-free paper